Publications by authors named "Vivian Altmann"

Claim this Profile
G
Genome-wide meta-analysis of short-tandem repeats for Parkinson's disease risk using genotype imputation.
Olena Ohlei, Kimberly Paul, Susan Searles Nielsen, David Gmelin, Valerija Dobricic, Vivian Altmann

Brain Commun· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
variants in Brazilian Gaucher disease patients.
Suelen Porto Basgalupp, Vivian Altmann, Filippo Pinto E Vairo, Ida Vanessa Doederlein Schwartz, Marina Siebert

Mol Genet Metab Rep· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Case-Control Study of the Effects of () and Coffee on Parkinson's Disease.
Márcio Schneider Medeiros, Artur Francisco Schumacher-Schuh, Vivian Altmann, Carlos Roberto de Mello Rieder

Front Neurol· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Rare Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis.
Paloma Gómez-Fernández, Aitzkoa Lopez de Lapuente Portilla, Ianire Astobiza, Jorge Mena, Andoni Urtasun, Vivian Altmann

Cells· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cortisol levels, motor, cognitive and behavioral symptoms in Parkinson's disease: a systematic review.
Nayron Medeiros Soares, Gabriela Magalhães Pereira, Vivian Altmann, Rosa Maria Martins de Almeida, Carlos R M Rieder

J Neural Transm (Vienna)· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor necrosis factor alpha polymorphisms are associated with Parkinson's disease age at onset.
Juliana D Lindenau, Vivian Altmann, Artur F Schumacher-Schuh, Carlos R Rieder, Mara H Hutz

Neurosci Lett· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of genetic, biological and pharmacological factors on levodopa dose in Parkinson's disease.
Vivian Altmann, Artur F Schumacher-Schuh, Mariana Rieck, Sidia M Callegari-Jacques, Carlos R M Rieder

Pharmacogenomics· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there a role for ADORA2A polymorphisms in levodopa-induced dyskinesia in Parkinson's disease patients?
Mariana Rieck, Artur F Schumacher-Schuh, Sidia M Callegari-Jacques, Vivian Altmann, Márcio Schneider Medeiros

Pharmacogenomics· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Val66Met BDNF polymorphism is associated with Parkinson's disease cognitive impairment.
Vivian Altmann, Artur F Schumacher-Schuh, Mariana Rieck, Sidia M Callegari-Jacques, Carlos R M Rieder

Neurosci Lett· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Polymorphisms in the dopamine transporter gene are associated with visual hallucinations and levodopa equivalent dose in Brazilians with Parkinson's disease.
Artur F Schumacher-Schuh, Carolina Francisconi, Vivian Altmann, Thais L Monte, Sidia M Callegari-Jacques

Int J Neuropsychopharmacol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DRD2 haplotype is associated with dyskinesia induced by levodopa therapy in Parkinson's disease patients.
Mariana Rieck, Artur F Schumacher-Schuh, Vivian Altmann, Carolina Lm Francisconi, Paulo Tb Fagundes

Pharmacogenomics· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis